<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37668024</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>06</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1008-8830</ISSN><JournalIssue CitedMedium="Print"><Volume>25</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>15</Day></PubDate></JournalIssue><Title>Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics</Title><ISOAbbreviation>Zhongguo Dang Dai Er Ke Za Zhi</ISOAbbreviation></Journal><ArticleTitle>[Research progress in systemic lupus erythematosus from 2021 to 2022].</ArticleTitle><Pagination><StartPage>785</StartPage><EndPage>790</EndPage><MedlinePgn>785-790</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7499/j.issn.1008-8830.2302150</ELocationID><ELocationID EIdType="pii" ValidYN="Y">1008-8830(2023)08-0785-06</ELocationID><Abstract><AbstractText>Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems, presenting a complex and diverse clinical manifestation. The heterogeneous treatment response and prognosis of SLE pose significant challenges to its diagnosis, classification, and homogeneous treatment. The emergence of new technologies and fields, such as synthetic biology, genomics, and proteomics, has contributed to a deeper exploration of the pathogenesis and biomarkers of SLE, facilitating precision diagnosis and treatment. This review summarizes the latest research data and achievements in SLE for the years 2021-2022, providing an overview and summary of relevant studies conducted in the past two years.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yong-Zhen</ForeName><Initials>YZ</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Second Xiangya Hospital, Central South University, Changsha 410000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Xiao-Chuan</ForeName><Initials>XC</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Second Xiangya Hospital, Central South University, Changsha 410000, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>chi</Language><PublicationTypeList><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>2021&#x2014;2022&#x5e74;&#x5ea6;&#x7cfb;&#x7edf;&#x6027;&#x7ea2;&#x6591;&#x72fc;&#x75ae;&#x7814;&#x7a76;&#x8fdb;&#x5c55;&#x76d8;&#x70b9;.</VernacularTitle></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhongguo Dang Dai Er Ke Za Zhi</MedlineTA><NlmUniqueID>100909956</NlmUniqueID><ISSNLinking>1008-8830</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="chi"><AbstractText>&#x7cfb;&#x7edf;&#x6027;&#x7ea2;&#x6591;&#x72fc;&#x75ae;&#xff08;systemic lupus erythematosus&#xff0c;SLE&#xff09;&#x662f;&#x4e00;&#x79cd;&#x7d2f;&#x53ca;&#x591a;&#x5668;&#x5b98;&#x7cfb;&#x7edf;&#x7684;&#x81ea;&#x8eab;&#x514d;&#x75ab;&#x6027;&#x75be;&#x75c5;&#xff0c;&#x4e34;&#x5e8a;&#x8868;&#x73b0;&#x590d;&#x6742;&#x591a;&#x6837;&#xff0c;&#x6cbb;&#x7597;&#x6548;&#x679c;&#x548c;&#x9884;&#x540e;&#x5f02;&#x8d28;&#x6027;&#x5927;&#xff0c;&#x7ed9;SLE&#x7684;&#x8bca;&#x65ad;&#x5206;&#x578b;&#x53ca;&#x540c;&#x8d28;&#x6027;&#x6cbb;&#x7597;&#x5e26;&#x6765;&#x4e86;&#x5de8;&#x5927;&#x6311;&#x6218;&#x3002;&#x4ee5;&#x5408;&#x6210;&#x751f;&#x7269;&#x5b66;&#x3001;&#x57fa;&#x56e0;&#x7ec4;&#x5b66;&#x3001;&#x86cb;&#x767d;&#x8d28;&#x7ec4;&#x5b66;&#x4e3a;&#x4ee3;&#x8868;&#x7684;&#x65b0;&#x6280;&#x672f;&#x3001;&#x65b0;&#x9886;&#x57df;&#x7684;&#x51fa;&#x73b0;&#xff0c;&#x6709;&#x52a9;&#x4e8e;SLE&#x53d1;&#x75c5;&#x673a;&#x5236;&#x3001;&#x751f;&#x7269;&#x6807;&#x5fd7;&#x7269;&#x7684;&#x6df1;&#x5165;&#x6316;&#x6398;&#xff0c;&#x63a8;&#x52a8;&#x4e86;SLE&#x7684;&#x7cbe;&#x51c6;&#x8bca;&#x7597;&#x3002;&#x8be5;&#x7efc;&#x8ff0;&#x603b;&#x7ed3;2021&#x2014;2022&#x5e74;&#x5ea6;SLE&#x6700;&#x65b0;&#x7814;&#x7a76;&#x6570;&#x636e;&#x548c;&#x6210;&#x679c;&#xff0c;&#x5bf9;&#x8fd1;2&#x5e74;&#x76f8;&#x5173;&#x7684;&#x7814;&#x7a76;&#x8fdb;&#x884c;&#x56de;&#x987e;&#x53ca;&#x603b;&#x7ed3;&#x3002;.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Diagnosis</Keyword><Keyword MajorTopicYN="N">Pathogenesis</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">Treatment</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>6</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>5</Day><Hour>5</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37668024</ArticleId><ArticleId IdType="pmc">PMC10484082</ArticleId><ArticleId IdType="doi">10.7499/j.issn.1008-8830.2302150</ArticleId><ArticleId IdType="pii">1008-8830(2023)08-0785-06</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tian R, Zhang D, Yao X, et al. . Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study[J]. Ann Rheum Dis, 2023, 82(3): 351-356. DOI: 10.1136/ard-2022-223035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard-2022-223035</ArticleId><ArticleId IdType="pmc">PMC9933169</ArticleId><ArticleId IdType="pubmed">36241363</ArticleId></ArticleIdList></Reference><Reference><Citation>Levinsky Y, Broide M, Kagan S, et al. . Performance of 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in a paediatric population: a multicentre study[J]. Rheumatology (Oxford), 2021, 60(11): 5142-5148. DOI: 10.1093/rheumatology/keab140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab140</ArticleId><ArticleId IdType="pubmed">33560345</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown GJ, Ca&#xf1;ete PF, Wang H, et al. . TLR7 gain-of-function genetic variation causes human lupus[J]. Nature, 2022, 605(7909): 349-356. DOI: 10.1038/s41586-022-04642-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04642-z</ArticleId><ArticleId IdType="pmc">PMC9095492</ArticleId><ArticleId IdType="pubmed">35477763</ArticleId></ArticleIdList></Reference><Reference><Citation>Fillatreau S, Manfroi B, D&#xf6;rner T. Toll-like receptor signalling in B cells during systemic lupus erythematosus[J]. Nat Rev Rheumatol, 2021, 17(2): 98-108. DOI: 10.1038/s41584-020-00544-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-020-00544-4</ArticleId><ArticleId IdType="pmc">PMC7747191</ArticleId><ArticleId IdType="pubmed">33339987</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng Y, Ma J, Yao C, et al. . The NCF1 variant p.R90H aggravates autoimmunity by facilitating the activation of plasmacytoid dendritic cells[J]. J Clin Invest, 2022, 132(16): e153619. DOI: 10.1172/JCI153619.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI153619</ArticleId><ArticleId IdType="pmc">PMC9374378</ArticleId><ArticleId IdType="pubmed">35788118</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng J, Wang Y, Han X, et al. . Clinical implications of a new DDX58 pathogenic variant that causes lupus nephritis due to RIG-I hyperactivation[J]. J Am Soc Nephrol, 2023, 34(2): 258-272. DOI: 10.1681/ASN.2022040477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2022040477</ArticleId><ArticleId IdType="pmc">PMC10103098</ArticleId><ArticleId IdType="pubmed">36261300</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandling JK, Pucholt P, Hultin Rosenberg L, et al. . Molecular pathways in patients with systemic lupus erythematosus revealed by gene-centred DNA sequencing[J]. Ann Rheum Dis, 2021, 80(1): 109-117. DOI: 10.1136/annrheumdis-2020-218636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218636</ArticleId><ArticleId IdType="pmc">PMC7788061</ArticleId><ArticleId IdType="pubmed">33037003</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X, Gu S, Hong SM, et al. . Amelioration of autoimmunity in a lupus mouse model by modulation of T-bet-promoted energy metabolism in pathogenic age/autoimmune-associated B cells[J]. Arthritis Rheumatol, 2023, 75(7): 1203-1215. DOI: 10.1002/art.42433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42433</ArticleId><ArticleId IdType="pubmed">36575806</ArticleId></ArticleIdList></Reference><Reference><Citation>Sosa-Hern&#xe1;ndez VA, Romero-Ram&#xed;rez S, Cervantes-D&#xed;az R, et al. . CD11c+ T-bet+ CD21hi B cells are negatively associated with renal impairment in systemic lupus erythematosus and act as a marker for nephritis remission[J]. Front Immunol, 2022, 13: 892241. DOI: 10.3389/fimmu.2022.892241.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.892241</ArticleId><ArticleId IdType="pmc">PMC9160198</ArticleId><ArticleId IdType="pubmed">35663936</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham R, Durkee MS, Ai J, et al. . Specific in situ inflammatory states associate with progression to renal failure in lupus nephritis[J]. J Clin Invest, 2022, 132(13): e155350. DOI: 10.1172/JCI155350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI155350</ArticleId><ArticleId IdType="pmc">PMC9246394</ArticleId><ArticleId IdType="pubmed">35608910</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki T, Bracero S, Keegan J, et al. . Longitudinal immune cell profiling in patients with early systemic lupus erythematosus[J]. Arthritis Rheumatol, 2022, 74(11): 1808-1821. DOI: 10.1002/art.42248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42248</ArticleId><ArticleId IdType="pmc">PMC10238884</ArticleId><ArticleId IdType="pubmed">35644031</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M, Johnson-Stephenson TK, Wang W, et al. . Mesenchymal stem cell-derived exosome-educated macrophages alleviate systemic lupus erythematosus by promoting efferocytosis and recruitment of IL-17+ regulatory T cell[J]. Stem Cell Res Ther, 2022, 13(1): 484. DOI: 10.1186/s13287-022-03174-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13287-022-03174-7</ArticleId><ArticleId IdType="pmc">PMC9509559</ArticleId><ArticleId IdType="pubmed">36153633</ArticleId></ArticleIdList></Reference><Reference><Citation>Bashant KR, Aponte AM, Randazzo D, et al. . Proteomic, biomechanical and functional analyses define neutrophil heterogeneity in systemic lupus erythematosus[J]. Ann Rheum Dis, 2021, 80(2): 209-218. DOI: 10.1136/annrheumdis-2020-218338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218338</ArticleId><ArticleId IdType="pmc">PMC7855438</ArticleId><ArticleId IdType="pubmed">32988843</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie RA, van Vollenhoven RF, Kalunian K, et al. . Trial of anti-BDCA2 antibody litifilimab for systemic lupus erythematosus[J]. N Engl J Med, 2022, 387(10): 894-904. DOI: 10.1056/NEJMoa2118025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118025</ArticleId><ArticleId IdType="pubmed">36069871</ArticleId></ArticleIdList></Reference><Reference><Citation>Caielli S, Cardenas J, de Jesus AA, et al. . Erythroid mitochondrial retention triggers myeloid-dependent type I interferon in human SLE[J]. Cell, 2021, 184(17): 4464-4479.e19. DOI: 10.1016/j.cell.2021.07.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.07.021</ArticleId><ArticleId IdType="pmc">PMC8380737</ArticleId><ArticleId IdType="pubmed">34384544</ArticleId></ArticleIdList></Reference><Reference><Citation>Fillatreau S. Antibodies against type I IFN: the bad guys self-restrain in systemic lupus erythematosus[J]. Cell Rep Med, 2023, 4(1): 100903. DOI: 10.1016/j.xcrm.2022.100903.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100903</ArticleId><ArticleId IdType="pmc">PMC9873922</ArticleId><ArticleId IdType="pubmed">36652912</ArticleId></ArticleIdList></Reference><Reference><Citation>Psarras A, Wittmann M, Vital EM. Emerging concepts of type I interferons in SLE pathogenesis and therapy[J]. Nat Rev Rheumatol, 2022, 18(10): 575-590. DOI: 10.1038/s41584-022-00826-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-022-00826-z</ArticleId><ArticleId IdType="pubmed">36097207</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x5b8b;&#x7ea2;&#x6885;. &#x513f;&#x7ae5;&#x98ce;&#x6e7f;&#x75c5;&#x56fd;&#x9645;&#x76f8;&#x5173;&#x8bca;&#x6cbb;&#x6307;&#x5357;&#x7cfb;&#x5217;&#x89e3;&#x8bfb;&#x4e4b;&#x4e00;: EULAR-ACR&#x7cfb;&#x7edf;&#x6027;&#x7ea2;&#x6591;&#x72fc;&#x75ae;&#x5206;&#x7c7b;&#x6807;&#x51c6;&#x89e3;&#x8bfb;[J]. &#x4e2d;&#x56fd;&#x5b9e;&#x7528;&#x513f;&#x79d1;&#x6742;&#x5fd7;, 2020, 35(4): 249-252. DOI: 10.19538/j.ek2020040601.</Citation><ArticleIdList><ArticleId IdType="doi">10.19538/j.ek2020040601</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues Fonseca A, Felix Rodrigues MC, Sztajnbok FR, et al. . Comparison among ACR1997, SLICC and the new EULAR/ACR classification criteria in childhood-onset systemic lupus erythematosus[J]. Adv Rheumatol, 2019, 59(1): 20. DOI: 10.1186/s42358-019-0062-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s42358-019-0062-z</ArticleId><ArticleId IdType="pubmed">31092290</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x4e2d;&#x534e;&#x533b;&#x5b66;&#x4f1a;&#x513f;&#x79d1;&#x5b66;&#x5206;&#x4f1a;&#x80be;&#x810f;&#x5b66;&#x7ec4; . &#x72fc;&#x75ae;&#x6027;&#x80be;&#x708e;&#x8bca;&#x6cbb;&#x5faa;&#x8bc1;&#x6307;&#x5357;&#xff08;2016&#xff09;[J]. &#x4e2d;&#x534e;&#x513f;&#x79d1;&#x6742;&#x5fd7;, 2018, 56(2): 88-94. DOI: 10.3760/cma.j.issn.0578-1310.2018.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.issn.0578-1310.2018.02.003</ArticleId><ArticleId IdType="pubmed">29429194</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x5f20;&#x8f89;, &#x6768;&#x5ff5;&#x751f;, &#x9c81;&#x9759;, &#x7b49;. &#x72fc;&#x75ae;&#x80be;&#x708e;&#x8bca;&#x7597;&#x89c4;&#x8303;[J]. &#x4e2d;&#x534e;&#x5185;&#x79d1;&#x6742;&#x5fd7;, 2021, 60(9): 784-790. DOI: 10.3760/cma.j.cn112138-20210609-00410.</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.cn112138-20210609-00410</ArticleId><ArticleId IdType="pubmed">34445813</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson A. Renal mononuclear phagocytes in lupus nephritis[J]. ACR Open Rheumatol, 2021, 3(7): 442-450. DOI: 10.1002/acr2.11269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr2.11269</ArticleId><ArticleId IdType="pmc">PMC8280821</ArticleId><ArticleId IdType="pubmed">34060247</ArticleId></ArticleIdList></Reference><Reference><Citation>Jesus D, Larosa M, Henriques C, et al. . Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity[J]. Ann Rheum Dis, 2021, 80(12): 1568-1574. DOI: 10.1136/annrheumdis-2021-220363.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-220363</ArticleId><ArticleId IdType="pubmed">34407927</ArticleId></ArticleIdList></Reference><Reference><Citation>Parra S&#xe1;nchez AR, Voskuyl AE, van Vollenhoven RF. Treat-to-target in systemic lupus erythematosus: advancing towards its implementation[J]. Nat Rev Rheumatol, 2022, 18(3): 146-157. DOI: 10.1038/s41584-021-00739-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-021-00739-3</ArticleId><ArticleId IdType="pubmed">35039665</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold J, Dass S, Twigg S, et al. . Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab[J]. Rheumatology (Oxford), 2022, 61(12): 4905-4909. DOI: 10.1093/rheumatology/keac150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac150</ArticleId><ArticleId IdType="pubmed">35266512</ArticleId></ArticleIdList></Reference><Reference><Citation>Urowitz MB, Aranow C, Asukai Y, et al. . Impact of belimumab on organ damage in systemic lupus erythematosus[J]. Arthritis Care Res (Hoboken), 2022, 74(11): 1822-1828. DOI: 10.1002/acr.24901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.24901</ArticleId><ArticleId IdType="pmc">PMC9805003</ArticleId><ArticleId IdType="pubmed">35439360</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao X, Ren Y, Zhao Q, et al. . Pharmacokinetics analysis based on target-mediated drug distribution for RC18, a novel BLyS/April fusion protein to treat systemic lupus erythematosus and rheumatoid arthritis[J]. Eur J Pharm Sci, 2021, 159: 105704. DOI: 10.1016/j.ejps.2021.105704.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejps.2021.105704</ArticleId><ArticleId IdType="pubmed">33440243</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand E, Pike M, Merrill JT, et al. . Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial[J]. Arthritis Rheumatol, 2023, 75(2): 242-252. DOI: 10.1002/art.42391.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42391</ArticleId><ArticleId IdType="pmc">PMC10100399</ArticleId><ArticleId IdType="pubmed">36369798</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill JT, Werth VP, Furie R, et al. . Phase 2 trial of iberdomide in systemic lupus erythematosus[J]. N Engl J Med, 2022, 386(11): 1034-1045. DOI: 10.1056/NEJMoa2106535.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2106535</ArticleId><ArticleId IdType="pubmed">35294813</ArticleId></ArticleIdList></Reference><Reference><Citation>Humrich JY, Cacoub P, Rosenzwajg M, et al. . Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial[J]. Ann Rheum Dis, 2022, 81(12): 1685-1694. DOI: 10.1136/ard-2022-222501.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard-2022-222501</ArticleId><ArticleId IdType="pubmed">35973803</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Tang D, Yin L, et al. . New insights for regulatory T cell in lupus nephritis[J]. Autoimmun Rev, 2022, 21(8): 103134. DOI: 10.1016/j.autrev.2022.103134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2022.103134</ArticleId><ArticleId IdType="pubmed">35690245</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Liu H, Yan H, et al. . Research advances on targeted-Treg therapies on immune-mediated kidney diseases[J]. Autoimmun Rev, 2023, 22(2): 103257. DOI: 10.1016/j.autrev.2022.103257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2022.103257</ArticleId><ArticleId IdType="pubmed">36563769</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie RA, Morand EF, Bruce IN, et al. . Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial[J]. Lancet Rheumatol, 2019, 1(4): e208-e219.</Citation></Reference><Reference><Citation>Morand EF, Furie R, Tanaka Y, et al. . Trial of anifrolumab in active systemic lupus erythematosus[J]. N Engl J Med, 2020, 382(3): 211-221. DOI: 10.1056/NEJMoa1912196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1912196</ArticleId><ArticleId IdType="pubmed">31851795</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatham WW, Furie R, Saxena A, et al. . Long-term safety and efficacy of anifrolumab in adults with systemic lupus erythematosus: results of a phase II open-label extension study[J]. Arthritis Rheumatol, 2021, 73(5): 816-825. DOI: 10.1002/art.41598.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41598</ArticleId><ArticleId IdType="pmc">PMC8252065</ArticleId><ArticleId IdType="pubmed">33225631</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin BH, Teng YKO, Ginzler EM, et al. . Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial[J]. Lancet, 2021, 397(10289): 2070-2080. DOI: 10.1016/S0140-6736(21)00578-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00578-X</ArticleId><ArticleId IdType="pubmed">33971155</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasni SA, Gupta S, Davis M, et al. . Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus[J]. Nat Commun, 2021, 12(1): 3391. DOI: 10.1038/s41467-021-23361-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-23361-z</ArticleId><ArticleId IdType="pmc">PMC8185103</ArticleId><ArticleId IdType="pubmed">34099646</ArticleId></ArticleIdList></Reference><Reference><Citation>You H, Zhang G, Wang Q, et al. . Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre[J]. Ann Rheum Dis, 2019, 78(10): 1441-1443. DOI: 10.1136/annrheumdis-2019-215455.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215455</ArticleId><ArticleId IdType="pubmed">31005902</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;nig N, Fiehn C, Wolf C, et al. . Familial chilblain lupus due to a gain-of-function mutation in STING [J]. Ann Rheum Dis, 2017, 76(2): 468-472. DOI: 10.1136/annrheumdis-2016-209841.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2016-209841</ArticleId><ArticleId IdType="pubmed">27566796</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J, Park Y, Jang SG, et al. . Baricitinib attenuates autoimmune phenotype and podocyte injury in a murine model of systemic lupus erythematosus[J]. Front Immunol, 2021, 12: 704526. DOI: 10.3389/fimmu.2021.704526.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.704526</ArticleId><ArticleId IdType="pmc">PMC8419414</ArticleId><ArticleId IdType="pubmed">34497607</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakayamada S, Tanaka Y. Pathological relevance and treatment perspective of JAK targeting in systemic lupus erythematosus[J]. Expert Rev Clin Immunol, 2022, 18(3): 245-252. DOI: 10.1080/1744666X.2022.2040988.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2022.2040988</ArticleId><ArticleId IdType="pubmed">35138987</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang T, Li B, Li M, et al. . Engineered cell membrane vesicles expressing CD40 alleviate system lupus nephritis by intervening B cell activation[J]. Small Methods, 2023, 7(3): e2200925. DOI: 10.1002/smtd.202200925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/smtd.202200925</ArticleId><ArticleId IdType="pubmed">36605001</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z, Jiang H, Xu X, et al. . Polymeric dexamethasone prodrugs attenuate lupus nephritis in MRL/lpr mice with reduced glucocorticoid toxicity[J]. Nanomedicine, 2022, 44: 102579. DOI: 10.1016/j.nano.2022.102579.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nano.2022.102579</ArticleId><ArticleId IdType="pmc">PMC9427713</ArticleId><ArticleId IdType="pubmed">35768036</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Sun J, Yuan Y, et al. . Proximity-enabled covalent binding of IL-2 to IL-2R&#x3b1; selectively activates regulatory T cells and suppresses autoimmunity[J]. Signal Transduct Target Ther, 2023, 8(1): 28. DOI: 10.1038/s41392-022-01208-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-01208-3</ArticleId><ArticleId IdType="pmc">PMC9871032</ArticleId><ArticleId IdType="pubmed">36690610</ArticleId></ArticleIdList></Reference><Reference><Citation>Mougiakakos D, Kr&#xf6;nke G, V&#xf6;lkl S, et al. . CD19-targeted CAR T cells in refractory systemic lupus erythematosus[J]. N Engl J Med, 2021, 385(6): 567-569. DOI: 10.1056/NEJMc2107725.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2107725</ArticleId><ArticleId IdType="pubmed">34347960</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackensen A, M&#xfc;ller F, Mougiakakos D, et al. . Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus[J]. Nat Med, 2022, 28(10): 2124-2132. DOI: 10.1038/s41591-022-02017-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02017-5</ArticleId><ArticleId IdType="pubmed">36109639</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>